Infermedica Secures $30M Funding for AI Medical Guidance

Infermedica Secures $30 Million in Series B Funding

Infermedica, a digital health innovator originating in Poland, has successfully completed a $30 million Series B funding round. This investment will bolster the company’s AI-powered solutions designed for symptom analysis and efficient patient triage.

One Peak spearheaded the funding initiative, with continued support from existing investors including Karma Ventures, the European Bank for Reconstruction and Development, Heal Capital, and Inovo Venture Partners. To date, the startup has amassed a total of $45 million in funding.

Company Mission and Platform

Established in 2012, Infermedica is dedicated to streamlining the process of pre-diagnosis, triage, and patient direction for healthcare professionals. The company’s core objective is to enhance the accessibility and affordability of primary care through the integration of automation within the healthcare sector.

Infermedica provides a B2B platform tailored for health systems, payers, and providers. This platform automates critical processes such as patient triage, initial intake procedures, and post-visit follow-up care.

Since its inception, Infermedica’s technology has been deployed across over 30 countries, supporting 19 languages, and has facilitated more than 10 million health assessments.

Core Offerings and Competitive Landscape

The company’s suite of products includes a preliminary diagnosis symptom checker, AI-supported software for call operators to facilitate timely triage decisions, and an API enabling the creation of bespoke diagnostic solutions.

Infermedica operates within a competitive market alongside companies like Ada Health and Babylon, all of which leverage the combined expertise of medical professionals and advanced algorithms to deliver symptom triage and patient guidance.

Future Development and Expansion Plans

According to Infermedica CEO Piotr Orzechowski, the newly acquired funds will be allocated towards the continued development of the company’s Medical Guidance Platform and the addition of new modules to encompass the complete spectrum of primary care.

Last year witnessed an 80% expansion of the Infermedica team, reaching a total of 180 specialists, encompassing physicians, data scientists, and engineers. The company anticipates nearly doubling its workforce within the next 12 months.

“We will prioritize investment in both our personnel and our product offerings,” stated Orzechowski. “This includes launching new platform modules and enhancing the underlying AI capabilities regarding disease coverage and precision.”

From a commercial standpoint, the company intends to solidify its presence in the U.S. and DACH regions, concentrating the majority of its sales and marketing efforts in these areas.

Long-Term Vision for AI in Healthcare

Orzechowski envisions a future where fully automated self-care bots will be readily available 24/7 within the next 5-10 years. These bots will assist providers in addressing low-acuity health concerns, such as common colds or urinary tract infections.

“The WHO projects a potential shortage of nearly 10 million doctors, nurses, and midwives globally by 2030,” Orzechowski explained. “Recognizing the limitations in rapidly increasing the number of trained healthcare professionals, our long-term strategy centers on AI becoming an integral component of modern healthcare systems.”

This integration will involve guiding patients, automating routine tasks, conserving the valuable time of clinical staff, and providing them with clinically sound technology.

Previous Funding Rounds

This Series B round follows a $10 million Series A investment secured in August 2020. That round was led by the European Bank for Reconstruction and Development (EBRD) and Heal Capital, with participation from existing investors Karma Ventures, Inovo Venture Partners, and Dreamit Ventures.